Johnson & Johnson (NYSE:JNJ) Shares Sold by Main Street Financial Solutions LLC

Main Street Financial Solutions LLC cut its position in Johnson & Johnson (NYSE:JNJ) by 10.1% in the fourth quarter, Holdings Channel reports. The firm owned 30,902 shares of the company’s stock after selling 3,490 shares during the period. Main Street Financial Solutions LLC’s holdings in Johnson & Johnson were worth $4,469,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Stenger Family Office LLC acquired a new position in Johnson & Johnson in the fourth quarter valued at $2,158,000. NFJ Investment Group LLC acquired a new position in Johnson & Johnson in the 4th quarter valued at about $10,774,000. Finward Bancorp purchased a new stake in Johnson & Johnson during the 4th quarter valued at approximately $1,554,000. United Capital Financial Advisors LLC lifted its position in Johnson & Johnson by 10.1% during the 4th quarter. United Capital Financial Advisors LLC now owns 291,841 shares of the company’s stock worth $42,206,000 after acquiring an additional 26,674 shares during the period. Finally, Delaney Dennis R increased its holdings in shares of Johnson & Johnson by 1.9% in the fourth quarter. Delaney Dennis R now owns 40,032 shares of the company’s stock valued at $5,789,000 after purchasing an additional 730 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.5 %

JNJ opened at $153.66 on Wednesday. The firm has a market cap of $370.29 billion, a P/E ratio of 23.11, a PEG ratio of 2.56 and a beta of 0.49. The business’s fifty day simple moving average is $159.39 and its 200 day simple moving average is $155.10. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.38%. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Analysts Set New Price Targets

JNJ has been the topic of a number of analyst reports. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Royal Bank of Canada restated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Stifel Nicolaus dropped their target price on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research report on Thursday, January 23rd. Barclays lifted their price target on Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research note on Tuesday, January 28th. Finally, Argus raised Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Eight analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $171.50.

Insider Activity

In related news, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.